Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking - Takeaways - MDSpire

Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking

  • May 1, 2026

  • 0 min

Share

  • 1

    A clinical trial indicates that semaglutide, a GLP-1 receptor agonist, reduces heavy drinking in patients with obesity and alcohol use disorder.

  • 2

    Participants receiving semaglutide experienced a 41.1% reduction in heavy drinking days, outperforming the placebo group by 13.7%.

  • 3

    The study involved 108 treatment-seeking patients who received either semaglutide or a placebo alongside cognitive behavioral therapy.

  • 4

    Semaglutide showed a lower number needed to treat (NNT) of 4.3, indicating greater clinical efficacy compared to existing alcohol use disorder medications.

  • 5

    Future research aims to explore the long-term effects of GLP-1s in larger populations to validate these promising findings.

Original Source(s)

Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking

  • May 1, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes